NewsRBR Buzz

Tyson Fury Tests Positive for Cocaine

Fury-Chisora-Scott Heavey-Getty Images
Photo by Scott Heavey/Getty Images

It seems that the Tyson Fury circus show has hit a new low. According to multiple sources, including, Fury has tested positive for benzoylecgonine, the main compound found in cocaine.

Fury recently pulled out of his October 29 rematch with former champion Wladimir Klitschko, because according to his promoter he was medically unfit.

Representatives for Fury, Klitschko, the British Boxing Board of Control and the United States’ Association of Boxing Commissions were made aware of the positive testing in a letter from VADA president Dr. Margaret Goodman.

“This letter is to advise you that the ‘A’ sample urine specimen number 4006253 collected from Tyson Fury on September 22, 2016 in Lancaster, England through his participation in the Voluntary Anti-Doping Association (VADA) program has been analyzed for anabolic agents, diuretics, beta-2 agonists, stimulants and drugs of abuse. The results of the analysis are as follows: Adverse. Urine specimen contains benzoylecgonine.”

In an interview with The Guardian in April of this year, Fury opened up about his battle with depression and finding a meaning for living.

“It’s either high or low. I’m either off my head on cocaine or down on the floor from a tranquiliser injection,” said Fury. “Most of the time, I’m just down and depressed like today, because for every high there’s a low.”

“I’m still trying to figure what life’s all about. Life’s about family, I suppose, being happy with your surroundings, and your wife and kids … But obviously I don’t fit in anywhere. I’ll be searching till the day I die,” said Fury.

Fury will likely be stripped of his heavyweight world title belts–though at this point that has to be the least of his concerns.


Alejandro "Alex" Burgos is a former Featured Columnist for Bleacher Report and the Founder & Editor-in-Chief of Round By Round Boxing. He is a professional blogger, SEO Consultant and Marketing Director at Capital Practice Consulting in Washington, DC.